Morbidity from In-hospital Complications is Greater Than Treatment Failure in Patients with Staphylococcus Aureus Bacteraemia
Overview
Authors
Affiliations
Background: Various studies have identified numerous factors associated with poor clinical outcomes in patients with Staphylococcus aureus bacteraemia (SAB). A new study was created to provide deeper insight into in-hospital complications and risk factors for treatment failure.
Methods: Adult patients hospitalised with Staphylococcus aureus bacteraemia (SAB) were recruited prospectively into a multi-centre cohort. The primary outcome was treatment failure at 30 days (composite of all-cause mortality, persistent bacteraemia, or recurrent bacteraemia), and secondary measures included in-hospital complications and mortality at 6- and 12-months. Data were available for 222 patients recruited from February 2011 to December 2012.
Results: Treatment failure at 30-days was recorded in 14.4% of patients (30-day mortality 9.5%). Multivariable analysis predictors of treatment failure included age > 70 years, Pitt bacteraemia score ≥ 2, CRP at onset of SAB > 250 mg/L, and persistent fevers after SAB onset; serum albumin at onset of SAB, receipt of appropriate empiric treatment, recent healthcare attendance, and performing echocardiography were protective. 6-month and 12-month mortality were 19.1% and 24.2% respectively. 45% experienced at least one in-hospital complication, including nephrotoxicity in 19.5%.
Conclusions: This study demonstrates significant improvements in 30-day outcomes in SAB in Australia. However, we have identified important areas to improve outcomes from SAB, particularly reducing renal dysfunction and in-hospital treatment-related complications.
Zhao C, Jiang Q, Wu W, Shen Y, Zhu Y, Wang X Ital J Pediatr. 2024; 50(1):130.
PMID: 39075514 PMC: 11287884. DOI: 10.1186/s13052-024-01703-z.
Wu H, Li M, Shou C, Shi F, Song X, Hu Q Front Cell Infect Microbiol. 2024; 14:1390053.
PMID: 38912203 PMC: 11190328. DOI: 10.3389/fcimb.2024.1390053.
Ceftaroline in CNS and ocular infections: a case series.
Siegrist E, Sassine J JAC Antimicrob Resist. 2024; 6(3):dlae095.
PMID: 38887612 PMC: 11180797. DOI: 10.1093/jacamr/dlae095.
Nong Y, Steinig E, Pollock G, Taiaroa G, Carter G, Monk I Commun Biol. 2024; 7(1):349.
PMID: 38514781 PMC: 10957945. DOI: 10.1038/s42003-024-06012-z.
McGuire E, Collin S, Brown C, Saito M Clin Infect Dis. 2024; 78(6):1443-1450.
PMID: 38315893 PMC: 11175704. DOI: 10.1093/cid/ciae056.